Table 2.
Reported allergic reactions | |
Antibiotic or antifungal | 8 (18.2%) |
Anti-inflammatory | 3 (6.8%) |
Neurologic agents | 1 (2.3%) |
Chemotherapy agent | 1 (2.3%) |
Vaccine | 5 (11.4%) |
Drug that contains similar ingredients as the COVID-19 vaccine | 4 (9.1%) |
SARS-CoV-2 vaccine | 40 (90.9%) |
Latency of allergic reaction | |
Less than 6 mo | 37 (84.1%) |
More than 6 mo | 7 (15.9%) |
Reported symptoms | |
Dermatologic | 28 (63.6%) |
Respiratory | 24 (54.5%) |
Cardiovascular | 11 (25%) |
Gastrointestinal | 4 (9.1%) |
Time between exposure to allergen and reported reactions | |
Less than 1 h | 31 (70.4%) |
More than 1 h | 13 (29.5%) |
Hospitalization for the allergic episode ICU |
3 (6.8%) 1 (33.3%) |
Treatment administered | |
Epinephrine | 9 (20.5%) |
Antihistamines | 36 (81.8%) |
Inhalers | 1 (2.3%) |
Cortisone | 7 (15.9%) |
Intravenous fluids | 2 (4.5%) |
No treatment | 6 (13.6%) |
Do not know | 1 (2.3%) |
Abbreviations: COVID-19, coronavirus disease 2019; FAAN, Food Allergy and Anaphylaxis Network; ICU, intensive care unit; NIAID, National Institute of Allergy and Infectious Diseases; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Latency: time between the reaction and the allergy evaluation.